TONG Minfeng,YANG Fan,LIU Jihong, et al. BC200 inhibits the temozolomide-induced apoptosis by mediating the maintenance of stemness of glioma cells[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2019, 49(7): 529-532,537.
Abstract:Objective: To investigate the role of serum long-chain non-coding RNA BC200 (lncRNA BC200) in glioma stem cells (GSCs) and related mechanism. Methods: Glioma U87 MG cells were cultured in neural stem cell culture medium and extracted into spherical growth GSCs. Immunofluorescence was used to detect the marker molecules CD133 and nestin of GSCs stem cells. Small RNA (siRNA) transfection silenced BC200 expression in GSCs. The GSCs were treated with Temozolomide (TMZ, 200 μmol·L-1) for 24 h, and the effect of TMZ on the morphology of suspended cells in GSCs was observed under light microscope. The expression of CD133, Bax, Bcl-2 and cleaved caspase-3 was detected by Western blot. Results: The extracted GSCs were isolated for spheroid growth, and the cell surface CD133 and nestin were positively expressed. After TMZ treatment of GSCs for 24 h, the ability of GSCs to form spheres did not change significantly, and the Bax, cleaved caspase-3 and Bcl-2 did not change significantly at 24 h. The expression of CD133 in GSCs was significantly decreased after silencing BC200. After BC200 silencing, TMZ treatment of GSCs showed that its ability to form a ball was significantly weakened, and the cells were dispersed. At 24 h, cleaved caspase-3 and Bax were up-regulated (45.36±4.25)% and (63.23±5.12)% (P<0.01). Bcl-2 was down-regulated (31.22±3.80)% (P<0.01). Conclusion: BC200 is able to maintain the dryness of glioma U87 MG cells, which promotes cell resistance to TMZ-induced apoptosis.
[1] 汲乾坤, 李建斌, 范阳华, 等. 下调CENP-W对人脑胶质瘤U87细胞的影响[J]. 中国病理生理杂志, 2017, 33(2): 263-270.
[2] HEYNCKES S, DAKA K, FRANOC P, et al. Crosslink between temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme[J]. BMC Cancer, 2019, 19(1): 117.
[3] CHEN M, SHARMA A, LIN Y, et al. Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells[J]. BMC Cancer, 2019, 19(1): 153.
[4] 孙红军, 林瑜亮, 党莹, 等. 异甘草素联合替莫唑胺对SHG44人脑胶质瘤干细胞增殖的影响[J]. 中华神经外科疾病研究杂志, 2016, 15(5): 405-409.
[5] 陈双双, 于正洪. 长链非编码RNAs在乳腺癌中的表达及其功能[J]. 临床肿瘤学杂志, 2015, 20(10): 943-947.
[6] IACOANGELI A, LIN Y, MORLEY E J, et al. BC200 RNA in invasive and preinvasive breast cancer[J]. Carcinogenesis, 2004, 25(11): 2125-2133.
[7] 夏东彦, 李英斌. 替莫唑胺在脑胶质瘤联合化疗中的应用进展[J]. 海南医学, 2017, 28(10): 1654-1656.
[8] ZHANG P, TANG M, HUANG Q, et al. Combination of 3-methyladenine therapy and Asn-Gly-Arg (NGR)-modified mesoporous silica nanoparticles loaded with temozolomide for glioma therapy in vitro[J]. Biochem Biophys Res Commun, 2019, 509(2): 549-556.
[9] 袁俐, 姜忠敏, 陈旭红, 等. 低氧诱导因子-1α去类泛素化修饰降低子宫内膜癌干细胞干性维持并增加对化疗敏感性的研究[J]. 中华医学杂志, 2017, 97(45): 3579-3582.
[10] 张华, 李苏宜. CD133与肿瘤干细胞研究进展[J]. 癌症, 2010, 29(3): 259-264.
[11] 喻敏成, 徐泱. 肿瘤干细胞研究进展[J]. 上海医药, 2017, 38(15): 28-31.
[12] 任浩, 王昌敏, 杨晓敏, 等. 血清长链非编码RNA BC200表达在胃癌诊疗中的应用价值[J]. 中华检验医学杂志, 2017, 40(2): 138-142.
[13] SHIN H, KIM Y, KIM M, et al. BC200 RNA: An emerging therapeutic target and diagnostic marker for human cancer [J]. Mol Cells, 2018, 41(12): 993-999.
[14] PAN W, LIU L, WEI J, et al. A functional lncRNA HOTAIR genetic variant contributes to gastric cancer susceptibility [J]. Mol Carcinog, 2016, 55(1): 90-96.